mRNA-Based Therapeutics & Vaccines: Driving a Shift in the Commercial Model

Time: 4:00 pm
day: Day Two


  • mRNA technology has potential for faster product design and easier-to-scale manufacturing: how this expands therapeutic and vaccine possibilities
  • The potential for speed and scale in development puts pressure on commercial organizations to be more agile, potentially changing the conversation with HCPs and on global equity in healthcare
  • Potential evolution of enabling factors that support faster-to-market therapies and vaccines: data generation, digitization, regulatory harmonization, etc